Q2 Earnings Estimate for LXRX Issued By Leerink Partnrs

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Lexicon Pharmaceuticals in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at $0.05 EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million.

LXRX has been the topic of several other reports. Piper Sandler cut their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Leerink Partners reissued a “market perform” rating and set a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals in a report on Monday, April 21st. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock opened at $0.54 on Friday. The firm has a market cap of $193.47 million, a P/E ratio of -0.71 and a beta of 1.07. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45. The firm has a 50-day moving average of $0.53 and a 200-day moving average of $0.71. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. raised its stake in shares of Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after acquiring an additional 7,758,371 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 301.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock worth $5,582,000 after acquiring an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 186.6% during the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock worth $4,877,000 after acquiring an additional 4,300,000 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at about $541,000. Finally, Tang Capital Management LLC lifted its position in shares of Lexicon Pharmaceuticals by 750.3% during the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 750,268 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.